Abstract:
Objective: To evaluate the prognostic signi cance of the new index designed by formulating neutrophil, lymphocyte, and platelet counts in patients with metastatic disease receiving immune checkpoint inhibitors (ICI) and its e ect on theimmune-related adverse events (irAEs). Study Design: Cohort study. Place and Duration of Study: Department of Medical Oncology, University of Manisa Celal Bayar, University of Aydin Adnan Menderes, and University of Ege, and Izmir Kent Hospital, Turkey, from January 2016 to April 2020. Methodology: Patients with metastatic disease receiving ICI su cient follow-up data were included. Patients, who had received treatment for a minimum of 3 months, were evaluated for the responseS.ystemic immune-in ammation index (SII) was calculated as neutrophil (/L) × (lymphocyte (/L) / platelet (/LT).he cut-o value was determined by examining the area under the receiver operating characteristic (ROC) curve for the SII value. The endpoints of this study included overall survival (OS) and progression-free survival (PFS). Results: A total of 168, patients who received ICI in the metastatic stage, were evaluated.The OS of the patients with low SII scores was 110.8 months (95% CI, 88.2-133.5), while patients with high SII scores were 36.0 months (95% CI, 28.4-43.6) and reached statistical signi cance (p <0.001). The results ofunivariate (HR=3.376, 95% CI, 1.986-5.739, p<0.001 and multivariate (HR=2.792, 95% CI, 1.495-5.215, p=0.011) analyses were statistically signi cant as well. Conclusion: The SII score in patients with metastatic disease receiving ICI was closely related to the prognosis. Patients with a high SII score are associated with a worse prognosis, these patients develop fewer irAEs.
Keywords:
Overall survival
,
Progressionfree survival
,
Nivolumab
,
Systemic immune in ammation index
,
0mmune checkpoint inhibitor
,
Pembrolizumab